Stockholm based Guard Therapeutics is trying to harness the natural properties of A1M (alpha-1-microglobulin) to protect the kidney

blonca9
Sep 21, 2024
1 min read

CEO Tobias Agervald explains how the lead program RMC-035 is being tested in conjunction with open heart surgery while smaller fragments of A1M are being developed for chronic kidney disease.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Stockholm based Guard Therapeutics is trying to harness the natural properties of A1M (alpha-1-microglobulin) to protect the kidney

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight